Navigation Links
Candidate drug provides benefit in SMA animal models
Date:6/4/2013

In a new publication that appears in Human Molecular Genetics, the laboratory of Christine DiDonato, PhD reports on their pharmacological characterization of the drug RG3039, demonstrating that it can extend survival and improve function in two spinal muscular atrophy (SMA) mouse models. They have determined the minimum effective dose and drug action, thus contributing to dose selection and exposure estimates for the first studies with RG3039 in humans. As in cellular assays, the animal studies have shown that drug treatment leads to improvement in nuclear gem/Cajal body numbers in motor neurons. Gem loss is a cellular hallmark of fibroblasts derived from SMA patients; gem numbers inversely correlate with SMA disease severity. In addition, the laboratory has shown improved functional outcomes, including treadmill walking and gait dynamics, in animals receiving the drug. The laboratory has been testing RG3039 in SMA mouse models with disease phenotypes ranging from mild to severe.

The collective results suggest that RG3039 positively modifies motor unit pathologies and dysfunction, and that it may have therapeutic benefit for SMA.

Spinal muscular atrophy (SMA) is a devastating hereditary disease that is a leading cause of infant and early childhood mortality. Motor neurons in the spinal cord are affected, resulting in muscle weakness and in many cases breathing problems. SMA is caused by insufficient levels of the survival motor neuron (SMN) protein; depending on the level of SMN protein, patients may have mild to severe forms of SMA. There is currently no cure for the disease.

The goal of early SMA drug discovery programs has been to identify small molecules that induce the SMN gene to produce sufficient levels of protein to improve motor neuron functioning in affected patients. A promising drug candidate is RG3039, which has been shown to increase nuclear gem/Cajal body numbers in cellular assays.

Says DiDonato: "We are very happy that our research was able to assist in the pharmacological characterization of RG3039 and contribute to dose selection and exposure estimates for the first studies with RG3039 in human subjects. We are indebted to my colleague, Nancy Kuntz, MD, and co-author laboratories of Drs. Jasbir Singh and Mike Kiledjian along with Repligen and Families of Spinal Muscular Atrophy (FSMA), who initiated the development of this drug candidate. The depth of our manuscript would not have been possible without this group collaboration. Also, it is reassuring that our results of improved motor unit dysfunction in SMA mice treated with RG3039 mirror the independent findings by the laboratories of Drs. Sumner and Ko. Improved neuromuscular function is an obvious goal for SMA therapies. Thus, this drug candidate warrants further investigation. Overall, this SMA candidate drug is an exciting time as we take another step forward towards developing therapies for SMA patients."


'/>"/>

Contact: Peggy Murphy
pemurphy@luriechildrens.org
773-755-7485
Children's Memorial Hospital
Source:Eurekalert

Related medicine news :

1. Novel drug candidates offer new route to controlling inflammation
2. Presidential candidates should address childhood obesity and bullying, poll says
3. Parc at Piedmont - East Cobb to Host Candidate Forum for Primary Elections
4. New candidate drug stops cancer cells, regenerates nerve cells
5. BWH researchers discover new vaccine candidate for Pseudomonas aeruginosa
6. No Truth to Candidates Claim That Rape Hinders Pregnancy, Experts Say
7. New oral drug candidate for African sleeping sickness
8. Katon Direct, a Healthcare Micro-Marketing Solutions Company, Launches Their New Website, Innovating the way Healthcare Companies Find the Most Qualified Candidates
9. NIH-developed candidate dengue vaccine shows promise in early-stage trial
10. NIH-funded researchers begin trial of Shigella vaccine candidates
11. Drugs targeting blood vessels may be candidates for treating Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... and services, is proud to announce it has joined the National Association for ... the interests of chronically ill, disabled, and dying Americans of all ages and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, ... the launch of a free, public-facing tool for analyzing the costs of various ... to provide comparative information to patients, providers, insurers and pharmaceutical companies about the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, a ... Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to equip ... in association with efforts by the American College of Surgeons, U.S. Department of ...
(Date:3/28/2017)... ... 28, 2017 , ... Usually, the impending arrival of warmer weather means the ... about a double chin, this means more anxiety than elation. The cosmetic dermatology experts ... people, a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)...  Las Vegas ophthalmology practice, Center For Sight, announced ... Dublin ), an implant that shunts ... intraocular pressure in patients with moderate to severe glaucoma. ... glaucoma that can lead to progressive optic nerve damage ... untreated. According to the National Eye Institute, ...
(Date:3/28/2017)... 2017 The U.S. Food and Drug ... adults with moderate-to-severe eczema (atopic dermatitis). Dupixent is ... adequately by topical therapies, or those for whom ... used with or without topical corticosteroids. ... approving new and innovative therapies for patients with ...
(Date:3/28/2017)... , March 28, 2017  "US Cancer Generics ... the various indicators and trend analysis related to ... in mainstream pharmaceutical market in US. The report ... the growth on cancer generics drugs in recent ... saving of billions of dollars for various stake ...
Breaking Medicine Technology: